Issue Brief

Letter from Pew Thanking Representatives Gingrey and Green for Leadership on New Antibiotics Legislation

December 12, 2013

The Honorable Phil Gingrey
U.S. House of Representatives
442 Cannon House Office Building
Washington, DC 20515

The Honorable Gene Green
U.S. House of Representatives
2470 Rayburn House Office Building
Washington, DC 20515

Dear Representatives Gingrey and Green:

The Pew Charitable Trusts thanks you for your continued leadership in addressing antibiotic resistance. You have already demonstrated your commitment to invigorating the antibiotic pipeline by championing the Generating Antibiotics Incentives Now (GAIN) Act, which was signed into law in July, 2012. The Antibiotic Development to Advance Patient Treatment (ADAPT) Act, introduced today, builds on that important legislation and is a welcome step towards establishing a new regulatory pathway to bring desperately-needed antibiotics to the patients who need them most.

Today, patients need treatments for increasingly common life-threatening infections such as those caused by carbapenem-resistant Enterobacteriaceae, or CRE. The Centers for Disease Control and Prevention recently classified CRE as an urgent threat, a “nightmare bacteria” that is resistant to our strongest antibiotics and is rapidly spreading across the U.S.

Your legislation would help streamline the regulatory pathway for antibiotics that could address CRE and other dangerous pathogens. It directs the Food and Drug Administration to approve new antibiotics for specific, limited populations of patients with life-threatening infections where few or no treatment options currently exist. Drugs approved under this pathway would be studied for use in smaller populations than other antibiotics. This will help lower development costs and make clinical trials more feasible. To reduce the likelihood that these drugs will be used in broader populations where the risk- benefit profile may be different, this legislation has several important safeguards. For example, it gives FDA the authority to review promotional materials before marketing and monitors how antibiotics approved under this pathway are being used.

The legislation also has some labeling requirements intended to communicate to physicians and other healthcare providers that these drugs have only been demonstrated to be safe and effective in limited populations. While these labeling requirements are a step in the right direction, we urge you to further strengthen them by requiring prominently placed language or other visual elements, so that the need to use these drugs prudently is immediately clear. Stronger labeling provisions would enhance the utility of this pathway and help ensure that patients who can be treated with other antibiotics are not put at unnecessary risk. Using these drugs in such a manner will also help preserve the effectiveness of these vital medicines. 

Lastly, we urge you to limit this bill to drugs for bacterial infections, as the need for new antibiotics, the dearth of new products in late-stage clinical trials, and the challenges associated with their development have been well-documented, as have the risks of indiscriminate prescribing. While new drugs for fungal infections would also be welcome, it is less clear that a limited population approach would be suited to antifungal development.

This new pathway tackles an important health problem with an approach that is good for public health and good for drug development. We look forward to working with you and other stakeholders to further improve the labeling language. Thank you again for your continued commitment to this important issue.


Nicole Mahoney
Senior Officer, Antibiotics and Innovation
The Pew Charitable Trusts

Allan Coukell
Senior Director, Drugs and Medical Devices
The Pew Charitable Trusts


Download the letter (PDF)

Date added:
Dec 12, 2013
Linda Paris, Tel: 202-540-6354
Antibiotics and Innovation Project
Antibiotic Innovation

Related Resources

The Super Bugs Causing Unmet Need and the Drugs to Fight Them

Issue Brief

Testing new antibiotics to treat highly resistant bacterial infections is especially difficult, since only a small number of patients contract such infections or meet the requirements to participate in clinical trials. Following are examples of hard-to-treat pathogens that present the greatest unmet needs today, and the types of drugs that are most likely to address them.


Pew Testimony Before The President’s Council of Advisors on Science and Technology

Other Resource

The President’s Council of Advisors on Science and Technology held a public meeting on April 4 to discuss the issue of antimicrobial resistance. Drug safety and innovation director Elizabeth Jungman testified on the need to spur the development of new antibacterial drugs.


IDSA, Pew Support Regulatory Pathway for Antibiotic Development

Media Coverage
Today, Pew applauds increasing bipartisan support in Congress to spur antibiotic development and meet the needs of patients facing the growing threat of drug-resistant pathogens. More

Tracking the Pipeline of Antibiotics in Development

Other Resource

Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. According to a Centers for Disease Control and Prevention report, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and 23,000 of them die. Doctors routinely encounter patients with infections that do not respond to available treatment, and when new drugs come to market, bacteria quickly develop resistance. To ensure that the supply of new antibiotics keeps pace with these evolving pathogens, it is necessary to have a robust pipeline of new drugs and innovative pathways to get this medicine to the patients who need it the most


From Lab Bench to Bedside: A Backgrounder on Drug Development

Other Resource

The process of creating new medicines is complex, time-consuming, and costly. Moving a potential therapy from concept to market can take between 10 and 15 years and cost developers as much as $1 billion. Indeed, industry also bears the cost of failure: For every drug that ultimately receives approval from the U.S. Food and Drug Administration, some 5,000 to 10,000 compounds don’t make it through the process.